200 mg

DRUG7 trials

Sponsors

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Kartos Therapeutics Inc., Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu, Minoryx Therapeutics S.L., Private

Conditions

000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. HenceAF occurence is even higherAdrenoleukodystrophyHCM is likely to affect around 20 million peopleHyperlipidemiaHypertrophic cardiomyopathy (HCM) is the most common genetically determined disease of the heartMetastatic non-squamous non-small cell lung cancer Metastatic Non-squamous non-small cell lung cancer

Phase 1

A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS

RecruitingCTIS2025-521508-23-00

Minoryx Therapeutics S.L.Adrenoleukodystrophy

Start: 2025-10-10Target: 73Updated: 2025-10-16

Phase 2

Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group.

Active, not recruitingIRCT2016020626401N1

Privateprostate cancer. Malignant neoplasm of prostate

Start: 2015-02-01Target: 40Updated: 2018-02-22

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

CVI PharmaceuticalsHyperlipidemia

Start: 2020-07-15End: 2022-03-15Target: 200Updated: 2020-06-23

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Active, not recruitingCTIS2024-513912-89-00

Kartos Therapeutics Inc.Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment

Start: 2018-12-13Target: 253Updated: 2025-09-17

Phase 3

Active, not recruitingLBCTR2024015481

Hôtel-Dieu de France University HospitalMetastatic non-squamous non-small cell lung cancer Metastatic Non-squamous non-small cell lung cancer

Start: 2024-01-02Target: 162Updated: 2026-02-02

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.

RecruitingCTIS2024-517610-15-00

Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniuatrial fibrillation, diabetes mellitus, heart failure +6

Start: 2024-03-28Target: 1116Updated: 2025-12-03

Phase 4

Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

CompletedCTIS2023-508743-43-00

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy000 people may be affected by HCM, 3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. Hence, AF occurence is even higher +25

End: 2025-09-16Target: 725Updated: 2024-09-16